Daratumumab-induced transient myopic shift

Maria A. Mavrommatis, Hoon Jung, Ajai Chari, Bart Barlogie, James G. Chelnis

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Purpose: To describe an unprecedented case of transient myopic shift induced by a chemotherapeutic agent, daratumumab. Observations: A 43-year-old emmetropic female with multiple myeloma experienced sudden onset of myopic shift during her first intravenous dose of daratumumab, an increasingly common FDA-approved chemotherapeutic agent. Her myopia was corrected with -4D lenses in both eyes, and the patient reports cessation of symptoms and disuse of lenses after two days. Conclusions and importance: A number of medications have been documented to induce transitory myopic shift, and this report now includes daratumumab among such agents. Further clinical findings regarding the mechanism and frequency of daratumumab-induced myopic shift are needed to further develop our understanding of its tangential effect on the eye.

Original languageEnglish
Pages (from-to)116-118
Number of pages3
JournalAmerican Journal of Ophthalmology Case Reports
Volume13
DOIs
StatePublished - Mar 2019

Keywords

  • Daratumumab
  • Multiple myeloma
  • Myopic shift
  • Transient myopia

Fingerprint

Dive into the research topics of 'Daratumumab-induced transient myopic shift'. Together they form a unique fingerprint.

Cite this